The idea of eliminating cancer cells by exploiting immune system as a treatment modality has come a long way.
Global Bispecific Antibody Market Insight 2028 Report Highlights:
- Research Methodology
- Global and Regional Market Analysis
- Global Bispecific Antibody Market Opportunity Assessment: > USD 20 Billion
- Market Sales Insight 2020 Till 2028
- Approved Drug Sales Insight Till Dec 2021(Updated Every Quarter)
- Approved Drug Sales Forecast Till 2028
- Approved Drug In Market: 3 Drugs
- Approved Bispecific Antibody Drug Patent, Price and Sales insight 2020 Till 2028
- Future Market Assessment By Indication Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
The idea of eliminating cancer cells by exploiting immune system as a treatment modality has come a long way. In comparison to conventional cancer therapies, immunotherapies have shown to be more advantageous as it delivers long-term protection against cancer, has minimal side effects, and avails treatment to more cancer types. Immunotherapy works by guiding system toward cancer-specific targets, followed by activation of immune system to mobilize the target, and produces response that can eradicate cancer targeted cells. The active research and development in this sector has led to development of several next generations therapeutic such as bispecific antibodies.
Bispecific antibodies are engineered to recognize two different epitopes. In comparison to conventional monoclonal antibodies, the bispecific antibodies show enhanced efficacy, binding affinity, and specificity; thus making them promising molecule in the management of cancer. Their most frequent application is to engage the CD3 antigen in T-cells in order to promote antibody-dependent cell-mediated cytotoxicity (ADCC), in which case they are called bispecific T-cell engagers (BiTEs). The only current marketed bispecifics globally are Roche’s Hemlibra (emicizumab-kxwh) for hemophilia A, Amgen’s Blincyto (blinatumomab) for acute lymphocytic leukemia (ALL), and Janssen’s Rybrevant (amivantamab) for non-small cell lung cancer.
The most promising targets for bispecific antibodies are CD19, CD20, and BCMA in blood malignancies and EGFR and HER2 in solid tumors. However, with the advancement in genomic fingerprinting and better understanding in the cancer biology has led to identification of other potential cancer targets which will further create opportunities for the pharmaceutical sector for the development of novel bispecific antibodies. Currently, the field of bispecific antibodies is highly unexplored and several pharmaceutical giants are actively indulging in research and development activities in this field. The major key players in the market include Amgen, Gilead Science, Roche, Zai Lab, Beigene, Akeso, Innovent Biologics, and Novartis. The pharmaceutical giants have adopted novel strategic alliances including collaboration, joint venture, and partnerships. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies.
The high costs involved in the development of bispecific antibodies with advanced techniques act as a major restrain for the market due to the complex production process, expensive biological and chemical materials, and clinical trials, as well as required safety, efficacy, and quality tests. Advanced equipment is required for the large-scale production of bispecific antibodies that encompass multiple disulfide bonds and post-translational modifications, and this equipment is expensive. However, the progress made by science had led to introduction of several next-generation technologies which reduce the overall cost of drug development and enhances productivity.
The global pipeline for novel bispecific antibodies is highly crowded and is indicated for the management of wide range of therapeutic conditions including cancer, autoimmune disorder, HIV, and other chronic disorders. As per our analysis, there are more than 1000 ongoing clinical trials which are evaluating the role of more than 300 bispecific antibodies which are discussed in report. In addition, researchers have also begun studying combination therapies as an alternative method to overcome the limits of bispecific antibody monotherapy, seeking to both improve the treatment efficacy and response duration. To date, combining T-cell engaging bispecific antibodies with checkpoint blockade therapy, especially anti-PD-L1 immune checkpoint inhibitors, remains one of the most promising combinations, which is expected to enter the market during forecast period.
As per our analysis, the global bispecific antibody market is expected to surpass US$ 20 Billion by 2028. There are many factors, such as increase in incidence of cancer, rise in healthcare expenditure, increased access to medical insurance, and technological advancements in cancer treatment therapies that fuel the growth of the global bispecific antibodies market. In addition, rising initiatives by government and subsequent development of favorable reimbursement policies also acts as driver to the market.
Contact:
Neeraj Chawla
Kuick Research
Research Head
+91-9810410366